Showing 1,641 - 1,660 results of 110,050 for search '(( 50 ((ms decrease) OR (a decrease)) ) OR ( 10 ((we decrease) OR (nn decrease)) ))', query time: 1.26s Refine Results
  1. 1641
  2. 1642
  3. 1643
  4. 1644
  5. 1645

    Time-dependent probability density functions for <em>T</em> and <em>S</em> from 10 000 member ensembles by Joseph D Daron (557053)

    Published 2013
    “…This question is at the heart of how we design and interpret climate model experiments for both science and policy support. …”
  6. 1646

    Identification, Synthesis, and Biological Evaluations of Potent Inhibitors Targeting Type I Protein Arginine Methyltransferases by Xiao Li (107004)

    Published 2022
    “…Compared to the type I PRMT inhibitor from our previous work (DCPR049_12), ZL-28-6 showed increased potency against CARM1 and decreased activity against other type I PRMTs. Moreover, ZL-28-6 showed better antiproliferation activities toward a series of solid tumor cells than DCPR049_12, indicating its broad spectrum of anticancer activity. …”
  7. 1647
  8. 1648
  9. 1649
  10. 1650
  11. 1651
  12. 1652
  13. 1653

    Gene clustering identifies up- and down-regulated groups that control development, pluripotency, and cell division. by Michael Shelton (382572)

    Published 2019
    “…<p>Pluripotent H9 hESCs were differentiated for 50 days as previously described [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0222946#pone.0222946.ref012" target="_blank">12</a>], beginning with high (7.5 μM or 10 μM) CHIR99021 concentrations. mRNA samples from the indicated time points were subjected to gene expression profiling. …”
  14. 1654
  15. 1655
  16. 1656

    Data Sheet 1_Reduced hemolytic complement activity in the classical pathway (CH50) is a risk factor for poor clinical outcomes of patients with infections: a retrospective analysis... by Hiroyuki Koami (3878434)

    Published 2025
    “…</p>Results<p>Of 2,726 patients who met the inclusion criteria, logistic regression models demonstrated that decreased CH50 is a significant predictor of 180-day mortality (OR: 0.98-0.99). …”
  17. 1657

    Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis by Chenlu Zhang (508309)

    Published 2022
    “…Evidence showed that intestinal FXR antagonism exhibited remarkable metabolic improvements in mice. Herein, we developed a series of betulinic acid derivatives as potent intestinal FXR antagonists, and <b>F6</b> was identified as the most potent one with an IC<sub>50</sub> at 2.1 μM. …”
  18. 1658

    Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis by Chenlu Zhang (508309)

    Published 2022
    “…Evidence showed that intestinal FXR antagonism exhibited remarkable metabolic improvements in mice. Herein, we developed a series of betulinic acid derivatives as potent intestinal FXR antagonists, and <b>F6</b> was identified as the most potent one with an IC<sub>50</sub> at 2.1 μM. …”
  19. 1659

    A Minor (<50%) Signet-Ring Cell Component Associated with Poor Prognosis in Colorectal Cancer Patients: A 26-Year Retrospective Study in China by Yinuo Tan (705777)

    Published 2015
    “…<div><p>Background</p><p>We performed a retrospective study to determine the cancer-specific survival of colorectal cancer patients with a component of signet-ring cells or mucin comprising < 50% of the tumor mass.…”
  20. 1660